Ovarian Cancer

Ovarian cancer spans multiple histotypes (e.g., high-grade serous, endometrioid, clear cell, mucinous) with recurrent molecular themes: BRCA alterations, homologous recombination deficiency (HRD), PI3K/AKT activation, and angiogenesis dependency. We provide antibodies and tools around CA125 (MUC16), HE4 (WFDC2), BRCA1/2, PARP, VEGF/VEGFR, FOLR1, plus pathway probes (PARP/ATR/CHK1/PI3K) for resistance and combination strategies.

Focus areas: HRD & PARPi biology, anti-angiogenesis & microenvironment, FOLR1 & ADCs, checkpoints & TILs

Ovarian cancer–related antibodies (curated)

Loading…

Hot topics & directions

  • HRD & PARPi resistance: Reversion mutations, fork protection (e.g., SLX4–MUS81), efflux reshaping therapeutic windows.
  • Anti-angiogenesis & stroma: Post-VEGF “vascular normalization” vs immune infiltration readouts.
  • Folate receptors & targeting: FOLR1-high subsets, antigen stability, ADC payload bystander effects.
  • Immunotherapy biomarkers: PD-L1/TMB/MSI predictive value varies by histotype—stratify analyses.

Related targets

Serum biomarkers
MUC16 (CA125), WFDC2 (HE4), CA72-4 (contextual)
DNA repair / replication stress
BRCA1, BRCA2, RAD51C/D, PALB2, ATM, ATR, CHEK1, PARP1/2
Growth & vasculature
VEGFA, KDR/FLT1 (VEGFRs), ERBB2 (HER2), FOLR1
Immune checkpoints & microenvironment
PDCD1 (PD-1), CD274 (PD-L1), CTLA4, TIGIT (trial-dependent)

Key signaling pathways

  1. HR-mediated DSB repair → PARP synthetic lethality
    BRCA/PALB2/RAD51C defects increase reliance on PARP-templated repair backups.
  2. PI3K–AKT–mTOR
    PIK3CA/PTEN lesions couple to proliferation/metabolism and resistance, often with MAPK feedback.
  3. VEGF–VEGFR / angiogenesis
    Neovascularization links ascites, drug delivery, and immune infiltration.
  4. Replication stress–ATR–CHK1
    High replication burden frames ATR/CHK1 inhibitor sensitivity studies.

Tool compounds (research use)

Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.

CompoundTargets / pathwaysExperimental notes
OlaparibPARP1/2Synthetic lethality in BRCA/HRD contexts; mind colony-formation vs replication-stress windows.
NiraparibPARP1/2/3 (clinical/preclinical context)Maintenance trials and HRD stratification matter; separate in vitro dose from toxicity narrative.
RucaparibPARP1/2/3Useful for PARPi-resistance models (fork protection, reversion mutations).
VeliparibPARP1/2Often paired with radio/chemo sensitization; pair HR biomarker readouts (e.g., RAD51 foci).
Berzosertib (VX-970)ATRReplication stress synthetic lethality with HRD/ATM loss; gate with cycle sync and dosing.
PrexasertibCHK1 (CHK2 off-target risk; model-dependent)Common preclinical combos with gemcitabine/platinum; separate apoptosis vs mitotic catastrophe.
AlpelisibPI3Kα (PIK3CA-mutant contexts)PI3K/AKT lesions are frequent; pair p-AKT with upstream receptor feedback experiments.